|Videos|June 22, 2023
Frontline Treatment Options for Lower-Risk MDS
Expert oncologists discuss standard-of-care frontline treatments for patients with lower-risk MDS.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA granted breakthrough therapy designation to enzomenib for relapsed/refractory acute leukemia with a KMT2A rearrangement.
The top 5 OncLive TV videos of the week cover insights in CRC at ESMO 2026, dMMR rectal cancer, chronic neutropenia, pediatric LGG, and MSS CRC.
The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.
Advertisement
Advertisement
Trending on OncLive
1
Sac-TMT Improves PFS and OS, Is Under FDA Priority Review in Previously Treated Endometrial Cancer
2
FDA Approves Talazoparib Plus Enzalutamide for Metastatic, HRR+ APMN/S Prostate Cancer
3
KEYNOTE-C93 Shows PFS Benefit With First-Line Pembrolizumab Monotherapy in dMMR Endometrial Cancer
4
Rinatabart Sesutecan Improves Survival in Platinum-Resistant Ovarian Cancer
5